Borisy Alexis 4

What Happened Alexis Borisy, a director of Relay Therapeutics (RLAY), was granted a derivative award covering 32,947 shares on June 9, 2026. The transaction is reported as an award/acquisition at a $0.00 price (derivative interest). This is a compensation grant (option award) rather than an open-market purchase or sale.

Key Details

• Transaction date: June 9, 2026; Filing date: June 10, 2026 (timely filing the next day).
• Instrument: Option/derivative award for 32,947 shares reported at $0.00.
• Vesting: Vests in full on the earlier of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders (per footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax withholding, or late-filing indication in this report.

Context This is a routine equity compensation grant to a director and should be viewed as part of director pay rather than a direct market signal like an open-market purchase or sale. Because it’s an option-style award (reported as a derivative) vesting within one year, the shares are not immediately tradable unless other plan terms allow.